The slide to be stained for Alpha-smooth muscle
(ASMA) comprised:
1. Appendix, 2. Leiomyosarcoma, 3. Embryonal rhabdomyosarcoma, 4. Normal
breast, 5. Gastrointestinal stromal tumour (GIST), 6. Liver.
All tissues were fixed in 10% neutral buffered formalin.
Criteria for assessing a ASMA staining as optimal included:
- A strong, distinct cytoplasmic staining of
all smooth muscle cells in the muscularis propria, lamina
muscularis mucosae and myofibroblasts lining the crypts and
surface epithelium.
- A strong, distinct cytoplasmic staining in
the myoepithelial cells in the basal layer of the breast glands
and ducts.
- A moderate to strong, distinct cytoplasmic
staining of the majority of the perisinusoidal cells (hepatic
stellate cell, "myofibroblasts") in the liver.
- A strong, distinct cytoplasmic staining of
virtually all the neoplastic cells of the leiomyosarcoma and the
GIST.
- A strong, distinct cytoplasmic staining of
the smooth muscle cells in virtually all vessels throughout the
specimens in the multitissue block.
114 laboratories submitted stains. 8 used
inappropriate antibodies (pan-actin Abs clone HHF35 and HUC1-1, or
h-caldesmon Ab clone h-CALD). 106 laboratories were assessed, of
which 32 achieved optimal marks (30 %), 35 good (33 %), 28
borderline (27 %) and 11 poor marks (10 %).
The following Abs were used:
mAb clone 1A4 (Dako, n=75; BioGenex, n=7; Ventana, n=7;
Sigma-Aldrich, n=6; NeoMarkers, n=5; BioCare, n=2; Cell Marque, n=1; Oncogene,
n=1; Linaris n=1)
mAb clone ASM-1 (Progen, n=1)
Optimal staining for ASMA in this assessment was obtained with the
mAb clone 1A4 (32 out of 105).
1A4: Protocols giving an optimal result were all based on
heat induced epitope retrieval (HIER) using either Tris-EDTA/EGTA pH
9 (28/51)*, Bond Epitope Retrieval Solution 2 (Bond, Leica-Microsystems)
(2/3), Target Retrieval Solution pH6,1 (TRS, Dako) (1/1) or Citrate
pH 6 (1/9) as HIER buffer. The mAb was typically diluted in the
range of 1:75 – 1:1.000 depending on the total sensitivity of the
protocol employed. Using these protocol settings 50 out of 57 (88 %)
laboratories produced a sufficient staining (optimal or good).
* (number of optimal results/number of
laboratories using this buffer)
All of 7 protocols based on 1A4 as a Ready-To-Use (RTU) Ab
gave an insufficient (weak or false negative) staining result,
despite the protocol settings being otherwise identical to those
based on a concentrated Ab giving sufficient results.
The most frequent causes of insufficient
staining were:
- Too low concentration of the primary antibody
- Too high concentration of the primary antibody
- No or insufficient epitope retrieval (particularly with citrate
buffer)
- Less successful RTU mAb clone 1A4.
In the assessment and in concordance with the
observations in the previous ASMA assessment in run 10 2004 almost
all laboratories were able to demonstrate ASMA in the smooth muscle
cells in the appendiceal muscle layers and the myoepithelial cells
of the breast, whereas the prevalent feature of the insufficient
staining in this run was a too weak or false negative staining of
the perisinusoidal cells,
the leiomyosarcoma and the GIST. This pattern was seen in 28 out of
the 39 insufficient results and typically caused by using the clone
1A4 too diluted or in the RTU format, or without HIER. A false
positive staining of nuclei was observed in 8 of the 39 insufficient
results. Efficient HIER combined with a too high concentration of
the clone 1A4 seemed to cause this pattern.
The perisinusoidal cells in the liver is a robust stain
quality indicator, as the majority of the laboratories with optimal
staining of the other tissues could demonstrate ASMA in these cells.
It has to be emphasized, that the perisinusoidal cells shall show an
as strong as possible reaction without any staining of the liver
cell cytoplasm or nuclei
This was the second run of ASMA. In the assessment of ASMA
in run 10, where 71 laboratories participated, 27 laboratories
obtained an insufficient mark. Each was given a specific
recommendation to improve their protocol. 20 of them submitted a new
ASMA stain in run 21. 13 followed the recommendation, of which 8
improved to good or optimal (62 %). 5 laboratories did not follow
the recommendation, and none of these obtained a sufficient staining
in run 21.
Two laboratories changed their entire system and can not be taken in
account – one improved, the other did not.
While the number of participants doubled from run 10 to the current
run, the results and observations are comparable.
Conclusion
The mAb clone 1A4 is a robust Ab for the demonstration of ASMA. HIER
is important to obtain an optimal result. Concentration of the
primary Ab should be carefully calibrated in order to avoid both a
false negative and false positive reaction. Liver is an appropriate
control tissue: The perisinusoidal cells must show a strong reaction
with no staining of the liver cells. |